Eliaz Therapeutics
Acute Kidney Injury (AKI) Device for Reduction of Galectin-3 Levels - Medical / Health Care - Clinical Services
The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibrosis that can be induced by circulating gal-3.
Most popular related searches
cancer treatment
acute kidney injury
kidney injury
healthcare service
medical care
medical clinic
clinical care
apheresis
injury reduction
The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
Stay in the loop!
Select your areas of interest to receive industry updates.